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Summary  Modern  tools  for  enzyme  discovery  combined  with  the  development  of  increasingly
reliable strategies  for  protein  engineering  have  greatly  expanded  the  range  of  enzymes  with
suitable properties  for  practical  applications.  This  situation  presents  enormous  opportunities
for the  design  of  sustainable  biocatalytic  strategies  for  the  production  of  high-value  chemicals.
Here, we  highlight  recent  contributions  from  our  laboratory  concerning  -transaminases  and
monoamine  oxidases,  two  enzyme  classes  that  have  been  exploited  for  the  industrial  scale  pro-
duction of  active  pharmaceutical  ingredients  or  key  chiral  intermediates.  Firstly,  we  describe
the development  of  novel  ‘smart’  amine  donors  which  overcome  inherent  challenges  associated
with controlling  the  equilibrium  position  of  -TA  catalyzed  processes.  Subsequently,  we  demon-
strate how  engineered  variants  of  monoamine  oxidase  developed  in  our  laboratory  have  been
applied as  biocatalysts  for  the  synthesis  of  a  diverse  range  of  active  pharmaceutical  ingredients
and alkaloid  natural  products.  Through  these  illustrative  examples,  we  hope  to  promote  the
wider application  of  enzymes  within  the  synthetic  community.
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n  recent  years,  biocatalysis  has  emerged  as  an  attrac-
ive  and  competitive  technology  for  the  production  of
ptically  pure  chiral  amines  and  amino  acids  (Höhne  and
ornscheuer,  2009).  Several  enzyme  classes  have  now  been
xploited  as  biocatalysts  in  industrial  scale  manufactur-
ng  processes,  including  -transaminases  (Savile  et  al.,
010),  monoamine  oxidases  (Li  et  al.,  2012)  and  ammo-
ia  lyases  (de  Lange  et  al.,  2011).  Particularly  signiﬁcant
ecent  examples  include  the  production  of  a  key  synthetic
ntermediate  for  Merck’s  hepatitis  C  drug  boceprevir  using
 an open access article under the CC BY license.
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a  heavily  engineered  MAO-N  variant  (Li  et  al.,  2012),  and
the  application  of  an  evolved  (R)-selective  -TA  for  the
synthesis  of  the  antidiabetic  compound  sitagliptin  (Savile
et  al.,  2010).  In  addition  to  these  more  ‘established’  enzyme
classes,  ‘emerging’  enzyme  families  such  as  imine  reduc-
tases  (Hussain  et  al.,  2015)  and  amine  dehydrogenases
(Abrahamson  et  al.,  2012)  are  likely  to  ﬁnd  synthetic  appli-
cations  in  the  coming  years.  Furthermore,  the  potential  to
exploit  these  enzymes  in  biocatalytic  cascade  processes  is
now  being  realized,  providing  new  opportunities  to  replace
multi-step  transformations  with  more  efﬁcient  single-step
processes.  A  recent  high-proﬁle  example  from  our  labora-
tory  involves  a  ‘hydrogen  borrowing’  biocatalytic  cascade
for  the  direct  conversion  of  alcohols  to  amines  (Mutti  et  al.,
2015).  In  this  perspective,  we  wish  to  highlight  a  selection
of  recent  developments  from  our  laboratory  involving  -TAs
and  MAOs,  enzyme  classes  with  broad  synthetic  potential
that  have  impacted  on  the  chemical  industry.
Xylylenediamine: a smart amine donor for
transaminase catalyzed processes
The  asymmetric  reductive  amination  of  ketones  with  ammo-
nia  has  been  identiﬁed  as  a  highly  desirable  transformation
for  use  in  the  pharmaceutical  industry  (Constable  et  al.,
2007).  This  fundamental  transformation  remains  a  consider-
able  challenge  in  organic  synthesis  which  typically  requires
a  multi-step  approach  (Nugent  et  al.,  2006),  impacting  upon
the  overall  efﬁciency  of  this  process.  In  recent  years,  bio-
catalytic  strategies  have  been  developed  to  overcome  these
existing  limitations  (Koszelewski  et  al.,  2010;  Mathew  and
Yun,  2012).  -TAs  are  a  family  of  pyridoxal-5′-phosphate
(PLP)-dependent  enzymes  that  utilize  a  sacriﬁcial  amine
donor  to  mediate  the  reversible  conversion  of  prochiral
ketones  to  the  corresponding  chiral  primary  amines  in  a sin-
gle  operation.  The  broad  substrate  scope,  high  stability  and
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Figure  1  Selected  examples  of  strategies  used  to  control  the  equi
amine donor  in  combination  with  pyruvate  degradation  using  the  LD
combined with  in  situ  evaporation  of  acetone  for  the  production  of  -value  chemicals  43
igh  levels  of  stereo  control  associated  with  engineered  -TA
ariants  makes  them  ideal  biocatalysts  for  use  in  synthetic
ransformations.  Despite  this  enormous  potential,  funda-
ental  challenges  associated  with  controlling  unfavourable
quilibrium  positions  are  hindering  the  widespread  appli-
ation  of  this  methodology  (Shin  and  Kim,  1999).  With  few
xceptions,  existing  strategies  rely  on  the  use  of  amine
onors  in  large  excess  combined  with  in  situ  removal  of
he  carbonyl  by-products  to  achieve  high  conversions  to  the
esired  amine  products.  The  most  widely  employed  strat-
gy  uses  alanine  as  the  amine  donor  and  relies  on  the  use
f  additional  enzymes  for  the  in  situ  removal  of  the  pyru-
ate  by-product  (Fig.  1A)  (Höhne  et  al.,  2008;  Koszelewski
t  al.,  2008;  Truppo  et  al.,  2009;  Shin  and  Kim,  1999).
nfortunately,  the  application  of  this  approach  for  scalable
mine  synthesis  is  limited  by  the  complexity  of  these  systems
nd  the  high  costs  associated  with  their  use.  Currently,  the
avoured  strategy  for  large  scale  transformations  involves
he  use  of  a  large  excess  of  isopropylamine  as  an  amine
onor  combined  with  the  selective  in  situ  evaporation  of  the
cetone  by-product,  an  approach  recently  exploited  in  sec-
nd  generation  biocatalytic  process  for  the  synthesis  of  the
nti-diabetic  API  sitagliptin  (Fig.  1B)  (Savile  et  al.,  2010).
sing  this  system,  good  to  excellent  conversions  of  selected
ubstrates  have  been  achieved  (Han  et  al.,  2015).  However,
or  those  substrates  which  suffer  from  unfavourable  equilib-
ium  positions,  to  obtain  the  low  concentrations  of  acetone
equired  to  achieve  high  conversions  represents  a  signiﬁcant
echnical  challenge  (Tufvesson  et  al.,  2011).
In  light  of  these  existing  challenges,  there  remains  a
lear  demand  for  the  development  of  broadly  applicable  and
perationally  simple  methods  of  conducting  -TA  mediated
rocesses.  In  this  regard,  we  recently  identiﬁed  ortho-
ylylenediamine  dihydrochloride  (1)  as  a  highly  effective
mine  donor  for  these  biocatalytic  transformations  (Green
t  al.,  2014).  The  use  of  stoichiometric  quantities  of  this
eagent  results  in  quantitative  conversions  to  the  desired
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sitagliptin.
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Figure  2  Biocatalytic  conversion  of  ketones  to  chiral  amines
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by-products  is  currently  being  exploited  in  our  laboratorysing diamine  1  as  the  donor,  leading  to  the  formation  of
oloured  polyisoindole  byproducts.
hiral  amine  products  in  the  absence  of  by-product  removal
ystems.  The  success  of  this  system  can  be  attributed  to  the
pontaneous  aromatization  of  the  cyclic  imine  by-product
2)  to  the  more  stable  isoindole  (3),  effectively  remov-
ng  this  component  from  the  system  (Fig.  2).  Signiﬁcantly,
his  electron  rich  isoindole  by-product  is  spontaneously
onverted  to  intensely  coloured  polymeric  derivatives  via
xidative  processes  (Bonnett  et  al.,  1973),  providing  an
perationally  simple  and  sensitive  method  to  detect  desired
ransaminase  activity.  These  coloured  structures  can  be  eas-
ly  detected  in  liquid  phase  transformations  or  directly  in
scherichia  coli  colonies  expressing  transaminase  genes.
uch  high-throughput  assays  are  extremely  desirable  for  the
dentiﬁcation  of  new  transaminases,  optimization  of  enzyme
roperties  through  directed  evolution  or  for  rapid  substrate
roﬁling  of  -TA  variants.
Using  ATA113,  an  (S)-selective  -TA  commercialized  by
odexis®,  benzaldehyde  (4)  and  a  panel  of  prochiral  ketones
5—11)  were  efﬁciently  converted  to  the  corresponding  pri-
ary  amines  with  excellent  conversions  and  high  optical
urity  using  <1.5  equiv.  of  diamine  (1)  (Table  1)  (Green  et  al.,
014).  Amination  of  dicarbonyl  (10)  proceeded  in  a  regio-
nd  stereoselective  manner  at  the  methyl  ketone  moiety.
his  was  followed  by  spontaneous  dehydrative  cyclization  to
a
n
t
Table  1  Conversion  of  4—11  into  the  corresponding  amines  using
Substrate  (5  mM)  Amine  donor  
4  1  
5 1  
6 1  
7 1  
8 1  
9 1  
10 1  
11 1  
11 1  
11 L-Ala  (no  p.r.)  
11 L-Ala  (LDH/GDH)  
GDH: glucose dehydrogenase; LDH: lactate dehydrogenase; n.a.: not aA.P.  Green,  N.J.  Turner
orm  the  corresponding  pyrroline  as  the  sole  product  as  pre-
iously  reported  (O’Reilly  et  al.,  2014a;  O’Reilly  and  Turner,
015).  The  biocatalytic  amination  of  1-indanone  (11)  repre-
ents  a  considerable  challenge  due  to  a  highly  unfavourable
quilibrium  position  (Shin  and  Kim,  1999).  Impressive  con-
ersions  of  54  and  73%  to  (S)-1-aminoindane  were  achieved
sing  1.0  and  1.5  equiv.  of  diamine  (1),  respectively.  In
ontrast,  a modest  21%  conversion  was  obtained  using
0  equiv.  L-alanine  and  the  LDH/GDH  by-product  removal
ystem.  In  the  absence  of  pyruvate  removal,  no  conver-
ion  was  detected  using  up  to  100  equiv.  of  alanine.  This
irect  comparison  demonstrates  the  remarkable  efﬁciency
f  1  as  an  amine  donor  in  transaminase  mediated  pro-
esses.  Diamine  (1)  has  been  shown  to  be  a  compatible
mine  donor  for  a  panel  of  twelve  (six  (S)-selective  and
ix  (R)-selective)  commercially  available  -TA  biocatalysts
upplied  by  Codexis®,  although  reduced  conversions  are  typ-
cally  observed  with  the  (R)-selective  enzymes  compared
ith  the  (S)-selective  counterparts.  Combined,  these  bio-
atalysts  display  an  extremely  broad  substrate  scope  for
tructurally  diverse  ketones.  Since  the  transaminase  mech-
nism  proceeds  via  two  half  equations,  the  substrate  scope
f  a  -TA  variant  is  unlikely  to  be  inﬂuenced  by  the  choice
f  amine  donor.
In summary,  the  use  of  ortho-xylylenediamine  as  an
mine  donor  provides  an  efﬁcient  and  operationally  sim-
le  method  for  the  biocatalytic  conversion  of  prochiral
etones  to  chiral  primary  amines.  This  technology  com-
ares  favourably  with  existing  chemical  methods  to  achieve
his  fundamental  transformation  which  typically  require  a
ulti-step  strategy.  The  generation  of  intensely  coloureds  a  high-throughput  screening  platform  for  enzyme  engi-
eering  and  substrate  proﬁling.  We  are  also  actively  seeking
o  identify  alternative  ‘smart’  amine  donors  which  retain
 ATA113  and  diamine  1.
Equiv.  Conv.  (%)  e.e.  (%)
1.1  98  n.a.
1.0  >99  >99  (S)
1.5  >99  >99  (S)
1.1  96  >99  (S)
1.2  97  >99  (S)
1.0  >99  78  (S)
1.0  >99  >99  (S)
1.0  54  >99  (S)
1.5  73  >99  (S)
100  n.d.  n.a.
10  21  >99  (S)
pplicable; n.d.: not detected; p.r.: pyruvate removal system.
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 MAO-N  D5  mediated  asymmetric  oxidative  desymmetrization.
Telaprevir  (12)  is  an  NS3.4A  serine  protease  inhibitor  used
for  the  treatment  of  hepatitis  C.  The  key  chiral  bicyclic
amino  acid  (13)  is  a  key  intermediate  for  the  production
of  teleprevir  which  is  difﬁcult  to  access  in  optically  pure
form  using  traditional  chemical  approaches  (Fig.  3).  We
devised  a  biocatalytic  approach  to  this  intermediate  involv-
ing  a  MAO-N  catalyzed  desymmetrization  (Köhler  et  al.,
2010).  Enantioselective  oxidation  of  prochiral  bicyclic  amine
(14)  proceeded  with  high  stereoselectivity  using  the  MAO-N
D5  variant  to  give  the  key  chiral  imine  (15),  which  exists
in  equilibrium  with  its  trimeric  form  (16).  Diastereose-
lective  addition  of  cyanide  and  subsequent  hydrolysis  of
the  amino-nitrile  intermediate  (17)  with  aqueous  HCl  gave
bicyclic  amino  acid  (13)  as  essentially  a  single  enantiomer
and  diastereoisomer  after  a  single  recrystallization.  In  par-
allel,  we  also  devised  an  alternative  synthetic  route  to
telaprevir  by  subjecting  chiral  imine  (15)  to  a  3-component
Ugi—Passerini  reaction  (Znabet  et  al.,  2010).
The  deracemization  of  chiral  amines  is  a  highly  desir-
able  transformation  which,  in  contrast  to  kinetic  resolution,
allows  the  desired  optically  pure  products  to  be  obtained
in  100%  theoretical  yield.  We  have  developed  a chemo-
enzymatic  strategy  to  achieve  this  transformation,  involving
repeated  cycles  enantioselective  oxidation  mediated  by
Accumulates
R1 R2
N
R3 R4
R1 R2
N
R3 R4
R1 R2
N
R3 R4
+
Enantioselective
Oxidation
MAO-N
Non-selective Chemical ReductionFigure  3  Synthesis  of  key  telaprevir  intermediate  15  via
the  efﬁciency  of  ortho-xylylenediamine  whilst  possessing
superior  properties  for  use  in  large  scale  manufacturing  pro-
cesses.
Synthetic applications of engineered MAO-N
variants
Monomaine  oxidase  from  Aspergillus  niger  is  a  ﬂavin  depen-
dant  enzyme  that  mediates  the  conversion  of  amines  to
the  corresponding  imines  utilizing  molecular  oxygen  as  the
stoichiometric  oxidant.  Wild-type  MAO-N  displays  a  rather
narrow  substrate  tolerance,  with  appreciable  levels  of  activ-
ity  limited  to  simple,  non-chiral  primary  amines  (e.g.,
butylamine,  benzylamine).  Over  a  number  of  years,  we  have
adopted  a  substrate  walking  approach  to  engineer  vari-
ants  that  are  able  to  tolerate  chiral  primary,  secondary  and
tertiary  amines  with  broad  structural  features  (Alexeeva
et  al.,  2002;  Carr  et  al.,  2003;  Dunsmore  et  al.,  2006;
Ghislieri  et  al.,  2013a).  The  key  to  success  of  this  evo-
lutionary  endeavour  was  the  development  of  a  substrate
independent  high-throughput  colony-based  assay  based  on
the  detection  of  the  H2O2 by-product  (Alexeeva  et  al.,  2002).
MAO-N  has  proven  particularly  amenable  to  protein  engi-
neering,  leading  to  the  generation  of  a  panel  of  synthetically
valuable  biocatalysts  which  have  recently  been  commercial-
ized.  Here  we  wish  to  highlight  key  synthetic  methodologies
which  have  been  developed  in  our  laboratory  employing
these  engineered  biocatalysts.  These  include  kinetic  reso-
lutions  (O’Reilly  et  al.,  2014b),  deracemizations  (Ghislieri
et  al.,  2013b),  oxidative  desymmetrizations  (Köhler  et  al.,
2010)  and  asymmetric  oxidative  Pictet—Spengler  reactions
(Ghislieri  et  al.,  2013a),  leading  to  the  production  of  a  wide
range  optically  pure  alkaloid  natural  products  and  active
pharmaceutical  ingredients.
Figure  4  Desymmetrization  of  chiral  amines  via  repeated
cycles of  MAO-N  promoted  enantioselective  oxidation  and  non-
selective  chemical  reduction.
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AO-N  combined  with  non-selective  chemical  reduction
f  the  resulting  imines  (or  iminium  ions)  with  BH3-NH3
Fig.  4)  (Alexeeva  et  al.,  2002).  This  methodology  has
een  exploited  for  the  deracemization  of  chiral  pri-
ary,  secondary  and  tertiary  amines,  including  biologically
ctive  natural  products  and  key  pharmaceutical  inter-
ediates.  A  recent  highlight  included  the  preparative
cale  deracemizations  of  4-chlorobenzhydrylamine  (18)
nd  phenyltetrahydroisoquinoline  (19)  which  are  important
hiral  intermediates  in  the  synthesis  of  the  active  pharma-
eutical  ingredients  levocetirizine  (20)  and  solifenacin  (21),
espectively  (Fig.  5)  (Ghislieri  et  al.,  2013a).  In  these  exam-
les  we  employed  our  recently  evolved  MAO-N  D11  variant
hich  was  speciﬁcally  engineered  for  activity  towards  the
terically  demanding  benzhydrylamine  motif  by  targeting
utations  in  the  small  active  site  pocket  and  in  the  substrate
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Figure  6  A  MAO-N/BBE  cascade  for  the  conversion  of  conversor  the  deracemization  of  API  building  blocks.
ntrance  channel  (Ghislieri  et  al.,  2013a).  The  high  levels  of
electivity  towards  (S)-4-chlorobenzhydrylamine  are  partic-
larly  impressive  when  considering  the  structural  similarity
etween  the  two  aryl  substituents.
In  collaboration  with  the  Kroutil  group,  we  recently
escribed  a  biocatalytic  cascade  involving  MAO-N  and  the
erbererine  bridge  enzyme  (BBE)  for  the  conversion  of
acemic  benzyl  substituted  isoquinolines  to  the  correspond-
ng  optically  pure  berbines  (Schrittwieser  et  al.,  2014).
eticuline  (22)  is  a  key  biosynthetic  intermediate  that  lies
t  the  branch  point  of  two  important  alkaloid  biosynthetic
athways,  with  the  (S)-enantiomer  involved  in  berbine
iosynthesis  and  the  (R)-enantiomer  feeding  into  the  mor-
hine  pathway.  Heterologously  expressed  BBE  mediated  the
elective  conversion  of  (S)-reticuline  to  (S)-scoulerine  (23)
ia  an  oxidative  C—C  bond  forming  process  (Fig.  6).  To
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conversion = 97%
e.e. = 99%
23)
)
ion  of  racemic  reticuline  to  optically  pure  (S)-scoulerine.
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overcome  the  maximum  50%  theoretical  yield  associated
with  this  kinetic  resolution,  we  exploited  our  MAO-N  der-
acemization  methodology.  Using  the  MAO-N  D11  variant,
racemic  reticuline  (22)  was  efﬁciently  converted  to  the
optically  pure  (S)-enantiomer  under  standard  conditions.  By
combing  these  deracemization  and  kinetic  resolution  pro-
cesses  into  a  single  operation,  the  conversion  of  racemic
reticuline  to  optically  pure  (S)-scoulerine  was  achieved  in
excellent  conversion  (23).  In  the  ﬁnal  process,  a  minor
adjustment  of  the  chemical  reducing  agent  from  NH3.BH3
to  morpholine.BH3 was  necessary  to  minimize  deactivation
of  the  BBE.
In  a  ﬁnal  example,  we  recently  described  a  novel  MAO-N
triggered  oxidative  Pictet—Spengler  transformation  for  the
synthesis  of  the  —carboline  natural  product  (R)-harmicine
(24)  (Fig.  7)  (Ghislieri  et  al.,  2013a).  The  development  of
this  methodology  allowed  us  to  conceive  an  alternative  dis-
connection  strategy  to  the  previously  reported  synthetic
routes.  Pyrrolidine  (25)  is  available  in  one  step  from
tryptamine  and  butane  1,4-diol  using  catalytic  hydrogen  bor-
rowing  technology  (Cami-Kobeci  et  al.,  2005).  Incubation  of
this  substrate  with  the  MAO-N  D9  variant  initially  resulted  in
the  generation  of  the  iminium  ion  intermediate  (26)  which
underwent  a  spontaneous  non-selective  cyclization  to  form
harmicine  as  a  mixture  of  enantiomers.  Under  the  reaction
conditions,  the  undesired  (S)-enantiomer  was  converted  to
the  naturally  occurring  (R)-enantiomer  via  rounds  of  MAO-
N  D9  promoted  enantioselective  oxidation  and  non-selective
chemical  reduction.  The  conversion  of  non-chiral  pyrrolidine
(25)  to  (R)-harmicine  occurs  in  99%  e.e.  with  83%  con-
version  and  formally  represents  a  biocatalytic  asymmetric
oxidative  Pictet—Spengler  reaction.  This  two-step  synthe-
sis  of  harmicine  from  tryptamine  represents  the  shortest
synthetic  route  reported  to  date,  and  presents  a  striking
example  of  how  biocatalytic  methodology  can  inspire  the
development  of  novel  synthetic  strategies  to  access  target
molecules  (Turner  and  O’Reilly,  2013).
Conclusion
Biocatalysis  is  now  widely  recognized  as  a  competitive  and
sustainable  technology  for  use  in  the  chemical  industry.
Today,  a  growing  number  of  enzyme  classes  are  available
with  suitable  properties  for  synthetic  applications  thanks  to
the  collaborative  research  efforts  of  scientists  across  a  range
of  disciplines.  Synthetic  chemists  will  continue  to  exploit
these  engineered  biocatalysts  in  increasingly  inventive  ways approach  to  the  synthesis  of  (R)-harmicine.
s  they  seek  to  develop  efﬁcient  synthetic  routes  to  high-
alue  molecules.  In  this  perspective,  we  speciﬁcally  focused
pon  recent  contributions  from  our  laboratory  involving
he  biocatalytic  synthesis  of  high-value  chiral  amines  with
-transaminases  and  monoamine  oxidases.  Through  the
xamples  presented,  we  wish  to  highlight  how  consideration
f  biocatalytic  methodology  during  retrosynthetic  planning
an  lead  to  conceptually  novel  approaches  to  the  construc-
ion  of  high-value  molecules  (Turner  and  O’Reilly,  2013).
n  the  coming  years,  increasingly  sophisticated  strategies
or  directed  evolution  combined  with  a  fundamental  under-
tanding  of  the  determinants  of  enzyme  activity/selectivity
t  the  molecular  level  will  greatly  speed  up  the  pro-
ess  of  biocatalyst  optimization  and  allow  the  creation  of
e  novo  enzyme  activities  (Hilvert,  2013).  Such  advances
ill  undoubtedly  contribute  enormously  to  the  widespread
mplementation  of  biocatalytic  methodology  throughout  the
hemical  industry.
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